麗新國際(00191.HK)年度盈轉虧至19.66億港元
格隆匯 10 月 23日丨麗新國際(00191.HK)公告,截至2020年7月31日止年度,公司實現營業額53.24億港元,同比減少19.45%;公司擁有人應占虧損19.66億港元,去年則盈利27.97億港元,盈轉虧;每股基本虧損5.067港元 。
(i)於回顧年度內並無收購附屬公司議價收購收益淨額;(ii)集團擁有及透過集團合營公司持有投資物業公平值減少,導致於回顧年度內確認來自重估集團投資物業重大公平值虧損及集團合營公司應占虧損;(iii)集團於回顧年度內若干使用權資產減值及若干物業、廠房及設備減值導致其他營運開支增加;及(iv)麗豐集團待售落成物業撇減至可變現淨值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.